Industry
Drug Manufacturers - General
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Loading...
Open
322.48
Mkt cap
175B
Volume
1.8M
High
328.25
P/E Ratio
41.60
52-wk high
346.85
Low
321.28
Div yield
0.03
52-wk low
260.52
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 6:55 pm
Portfolio Pulse from Avi Kapoor
May 09, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:48 am
Portfolio Pulse from Shanthi Rexaline
May 09, 2024 | 11:27 am
Portfolio Pulse from Benzinga Insights
May 08, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Insights
May 07, 2024 | 6:45 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
May 06, 2024 | 2:17 pm
Portfolio Pulse from Shanthi Rexaline
May 05, 2024 | 7:16 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.